// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Using Whole-Exome Sequencing to Identify PKD1 and PKD2 in 50,000 UK Biobank Participants

Sukcharoen Kittiya - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Polycystic kidney disease 2 with or without polycystic liver disease

N/A

Identifying and Assessing the Phenotypic Features of HNF1B Deletions and Duplications in UK Biobank

Sukcharoen Kittiya - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Global Real-World Evidence of Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Maiese BrettA - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Autosomal dominant polycystic kidney disease

SAMSCA

Small-Molecule Allosteric Activators of Long-Form PDE4 Enzymes Suppress Cystogenesis in Models of ADPKD

Henderson David�James peter - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Autosomal dominant polycystic kidney disease

N/A

STAGED-PKD: An Enriched, Seamless, Two-Stage Study for Venglustat Assessment in ADPKD

Perrone RonaldD - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Autosomal dominant polycystic kidney disease

N/A

STAGED-PKD: Patient Enrichment and Modeling-Driven Efficient ADPKD Trial Design

Perrone RonaldD - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Autosomal dominant polycystic kidney disease

N/A

End-of-Study Results from ACQUIRE: A Study Measuring Quality of Life, Treatment Preference, and Treatment Satisfaction of Autosomal Dominant Polycystic Kidney Disease Patients in Europe

Joly Dominique - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Autosomal dominant polycystic kidney disease

N/A

Glucosylceramide Synthase Inhibition with Venglustat in Classic Fabry Disease Patients Leads to Progressive Reduction of Endothelial Cell Globotriaosylceramide Inclusion Volume

Najafian Behzad - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Fabry disease

N/A

ILLUMINATE-B, a Phase 3 Open-Label Study to Evaluate Lumasiran, an RNAi Therapeutic, in Young Children with Primary Hyperoxaluria Type 1 (PH1)

Michael Mini - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Primary hyperoxaluria type 1

N/A

PHYOX3: A Long-Term, Open-Label Extension Trial of Nedosiran in Patients with Primary Hyperoxaluria Type 1, 2, or 3

Coenen Martin - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Primary hyperoxaluria type 1

N/A

Epigenome-wide Association Study of Kidney Function

Franceschini Nora - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

RhoA-Rac1-CDC42 Regulators as Candidates for Monogenic Nephrotic Syndrome

Halawi AbdulA - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Nephrotic syndrome

N/A

Results from the Ongoing Phase 2 Open-Label Extension Study of Lumasiran, an Investigational RNAi Therapeutic, in Patients with Primary Hyperoxaluria Type 1 (PH1)

Frishberg Yaacov - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Primary hyperoxaluria type 1

N/A

Using Clustering to Facilitate Gene-Based Rare-Variant Collapsing for a Diverse Cohort of FSGS Patients

Povysil Gundula - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Focal segmental glomerulosclerosis

N/A

Efficient Follow-Up and Its Effects on Questionnaire Responses in the EQUAL Study in the United Kingdom

Gates EmerR - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

N/A

Outcomes of Haemodialysis in Incident Elderly Haemodialysis Patients: Single-Centre Experience

Gama Rouvick - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predictors of Functional Status Change in Patients with CKD Between Two Hip Fracture Events: A 6-Year Prospective Study

Wu Henry - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Which Parameters Best Predict Mortality After Hip Fracture for Patients with CKD? Insights from a 6-Year Prospective Analysis

Wu Henry - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Mortality Outcomes of Dialysis Patients Who Sustained Neck of Femur Fractures in a Tertiary London Renal Centre

Reeve EleanorIsabel - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Low- vs. Standard-Dose Rituximab for Induction and Maintenance Treatment of ANCA-Associated Vasculitis in Elderly Patients: A Single-Centre Observational Study

Rehman Shams Ur - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Cyclophosphamide

Copyright © 2026. QuantiNova All rights reserved